

Short communication

A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence

Conor K. Farren^{a,b,*}, Michael Scimeca^b, Ran Wu^a, Stephanie O. Malley^a

^a Yale University School of Medicine, Department of Psychiatry, Substance Abuse Treatment Unit, 1 Long Wharf, New Haven, CT 06419, United States

^b Mount Sinai School of Medicine, Department of Psychiatry, Bronx Veterans Administration Medical Centre, 130 West Kingsbridge Road, Bronx, NY 10468, United States

Received 24 December 2007; received in revised form 6 June 2008; accepted 6 June 2008

Available online 21 July 2008

Abstract

Introduction: Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone would be augmented by concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI).

Methods: One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis.

Results: Compliance and attendance rates were comparable and high. The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or on secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse events were similar for the two conditions.

Conclusions: As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone.

© 2008 Elsevier Ireland Ltd. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

Keywords: Alcohol dependence; Sertraline; Naltrexone; Clinical trial; Alcohol typology

1. Introduction

The FDA approval of the opioid antagonist naltrexone on the basis of two successful clinical trials (O'Malley et al., 1992; Volpicelli et al., 1992) opened a new vista for the use of pharmacotherapy in conjunction with psychotherapy to treat alcohol dependent individuals. With the publication of further positive trials of naltrexone (for reviews, see Kranzler and Van Kirk, 2001; Pettinati et al., 2006) including a large NIH sponsored multi-site study (Anton et al., 2006), it has become clear that naltrexone has a useful place in the range of treatment options.

Strategies to further enhance treatment response are being examined, including long acting naltrexone formulations (Garbutt et al., 2005; Kranzler et al., 2004; O'Malley et al., 2007) and combination therapies (e.g., Anton et al., 2006; Johnson et al., 2000; Keifer et al., 2003).

Several lines of research suggest that selective serotonin reuptake inhibitors (SSRIs) may be useful for augmenting naltrexone response. The serotonin system has long been found to be abnormal in preclinical and clinical studies of alcoholism (LeMarquand et al., 1994a,b). Preclinical models have also shown that the combination of an SSRI and naltrexone results in greater suppression of drinking compared to either drug alone (Zink et al., 1997; Rezvani et al., 2000). Potential additive effects are also suggested by preclinical work showing that fluoxetine reduces stress-induced reinstatement of drinking and naltrexone reduces alcohol reinstatement (Le et al., 1999). Although most

* Corresponding author at: St. Patrick's Hospital, James Street, Dublin 8, Ireland. Tel.: +353 1 2493523; fax: +353 1 6798865.

E-mail address: cfarren@stpatsmail.com (C.K. Farren).

clinical trials find that SSRIs are ineffective in treating alcohol dependence in unselected patients (Mann, 2004), some SSRIs may have therapeutic benefit in at least a typology-based subgroup (Kranzler et al., 1996; Pettinati et al., 2001; Tiihonen et al., 1996). For example, Pettinati et al. (2001) found increased abstinence with the use of 200 mg of sertraline in Type A (less severe) alcohol dependence. Finally, preliminary evidence from small open label studies combining naltrexone with agents targeting the serotonin system suggested benefit in non-depressed alcohol dependent patients (Farren et al., 2000; Johnson et al., 2000).

We thus examined the addition of the SSRI sertraline to naltrexone, in combination with standard cognitive behavioral psychotherapy, in a 12-week double-blind placebo-controlled trial in non-depressed alcohol dependent individuals. Exploratory analyses examined whether age of onset (early versus late) influenced the results.

2. Materials and methods

The study was carried out at two sites, Yale University School of Medicine in New Haven, CT and Mount Sinai School of Medicine in New York City. The protocol was approved by the local IRBs and all participants provided informed consent.

2.1. Medication

Participants were randomly assigned to one of two medication groups. The naltrexone only group received naltrexone 12.5 mg daily for 3 days, 25 mg daily for 4 days, and 50 mg daily for the next 11 weeks, together with placebo sertraline. The combination group received the same naltrexone regimen, but simultaneously received sertraline 50 mg daily for 2 weeks, followed by 100 mg daily for 10 weeks. Groups were randomized within site according to a computerized schedule. Pill counts were performed weekly for the first 2 weeks, and biweekly for the next 10 weeks. Participants also self-reported medication compliance. Riboflavin was added to the sertraline/placebo capsules by the dispensing pharmacy and urinary fluorescence was measured at the same frequency (Del Boca et al., 1996).

2.2. Therapy

Subjects received weekly group relapse prevention psychotherapy (Project Match Research Group, 1997) for 12 weeks. Therapy sessions were conducted by masters or doctoral level psychotherapists and subjects were encouraged to attend Alcoholics Anonymous meetings.

2.3. Recruitment

Potential participants responded to local advertisements. Subjects ranged in age from 19 to 64 and met DSM-IV criteria for alcohol dependence (Spitzer and Williams, 1992). Between 5 and 30 days of alcohol abstinence prior to medication administration was required. Subjects were excluded if they met criteria for current abuse or dependence on any substance other than nicotine or alcohol, had a current Axis I disorder in addition to alcohol dependence (including major depression), or reported any past illicit opiate use. Other exclusions were significant liver disease (AST or ALT >300% of upper limit of normal or bilirubin >110% of upper limit of normal), a positive BAL during evaluation, or any major physical illness.

2.4. Assessments

The Addiction Severity Index (ASI) (McLellan et al., 1980), the Obsessive Compulsive Drinking Scale (OCDS) (Anton et al., 1996), the Beck

Depression Inventory (BDI) (Beck et al., 1961), and the Time-line Follow-back Interview (TLFB) (Sobell et al., 1988) were completed at baseline. Blood tests including serum aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) were obtained at baseline, 4 and 12 weeks. The following assessments were made weekly for the first 2 weeks and biweekly subsequently: the OCDS, the BDI, the TLFB, and a side-effects scale.

The primary outcomes included time to first drink and time to first relapse to heavy drinking (with relapse defined as 5 drinks in 1 day for men, and 4 drinks in 1 day for women). Percent days abstinent, number of drinks per drinking day for drinkers, change in Obsessive Compulsive Drinking Scale total scores, and ALT and GGT change from baseline were secondary outcomes.

2.5. Data analysis

Data were analyzed using SAS Version 9.1 (SAS Institute, Inc., Cary, NC). The primary analysis was conducted on the intention to treat sample ($n=111$). The survival analysis with maximum likelihood method was used to analyze the time-to-event outcomes. Missing data were censored. Mixed models were used for repeated outcomes and Analysis of Variance was applied to all other continuous outcomes. Site was a covariate in the analyses.

3. Results

3.1. Subject characteristics

The study was completed over 5 years. A total of 605 patients (299 Yale, 306 Mt. Sinai) were screened to produce randomization of 113 subjects (41 Yale, 72 Mt. Sinai) over the two sites. The majority of patients were ineligible for randomization because of the presence of depressive symptoms or failure to follow up. Two subjects were subsequently excluded from the intention to treat analysis at Mt. Sinai because they failed to meet entry criteria yielding a final sample of 111. Although participants at the two sites were similar in most characteristics, the Mt. Sinai group had a higher percentage of participants with high school education or greater (98.5% versus 78.1%, $p < .001$), had fewer Whites (61.2% versus 87.8%, $p < .01$), and reported fewer baseline drinks per drinking day (5.7 ± 2.90 versus 10.0 ± 6.0 , $p < 0.01$).

Table 1 presents the baseline characteristics of the sample. Fifty-seven participants received naltrexone with sertraline and 54 subjects received naltrexone and placebo. Twenty-three of the combination group did not complete, with 11 lost to follow up, 6 having poor compliance, and 6 due to side effects. Fourteen of the placebo group did not complete with 10 being lost to follow up, 2 having poor compliance, and 2 due to side effects.

3.2. Compliance

During treatment, medication compliance rates by pill count and urinary riboflavin were similar. The number of therapy sessions attended was equivalent, with 7.3 (± 0.5) for the combination group and 8.5 (± 0.3) for the placebo group. The number and percentage of each group with complete drinking data was also not significantly different between the combination group (42, 73.7%) and the placebo group (44, 81.5%).

Table 1
Baseline characteristics and drinking outcomes [mean \pm S.D.]

Characteristic	Naltrexone + Sertraline ($N=57$)	Naltrexone + Placebo ($N=54$)
Age	41.5 (9.55)	44.9 (9.68)
Male gender (%)	80.7	83.3
Race or ethnic group (%)		
White	71.4	71.2
Black	12.5	11.5
Hispanic	10.7	11.5
Other	5.4	5.8
Marital status		
% Married or living with partner	33.9	46.2
High school or greater	91.1	90.4
Age of onset of alcohol-related problems	30.8 (10.09)	33.3 (8.72)
% Days abstinent	29.3 (19.13)	25.6 (18.66)
Drinks per drinking day in previous 90 days	7.3 (4.82)	7.4 (4.78)
ALT	7.8 (5.72)	7.3 (5.30)
GGT	92.7 (122.39)	118.0 (208.76)
Drinking outcomes (%)		
Drinks per drinking day for drinkers ^a	5.3 (4.06)	4.3 (4.29)
Drinks per drinking day for all subjects	2.8 (3.95)	3.0 (4.09)
Percent days abstinent	79.2 (30.48)	84.5 (17.47)
OCDS total ^b	7.4 (5.50)	7.7 (6.23)
GGT change from baseline	26.4 (44.70)	60.5 (170.88)
ALT change from baseline	4.0 (33.9)	10.3 (23.8)

No significant differences between groups in their baseline characteristics or drinking outcomes.

^a $N=28$ for naltrexone + sertraline and $N=37$ for naltrexone + placebo.

^b Mixed model.

3.3. Outcomes

Time to the first day of drinking was longer, although not statistically different ($p=0.10$; Fig. 1) for the combination group (49.1% abstinent) compared to the naltrexone alone group (31.5% abstinent). There was no significant difference between groups in time to first relapse to heavy drinking ($p=0.13$), time to second drink ($p=0.13$), or in percent days abstinent ($p=0.19$). Among those subjects who drank ($n=64$), the groups were sim-

ilar on drinks per drinking day ($p=0.19$). There was also no significant difference in change in GGT ($p=0.30$), ALT scores ($p=0.31$), BDI or OCDS scores.

Rates of the majority of reported side effects, including disrupted sleep, decreased sex drive, low energy, nausea, headache and altered appetite were not significantly different between groups. There were more reported sexual side effects in the combination group (68% versus 24%, $p<0.001$). The incidence of reported side effects peaked at week one in both groups (data not shown), with the frequency and intensity of most side effects, except sexual side effects, declining over time.

Exploratory analyses of outcomes by subtype of alcoholism were also completed with age of onset used as the criterion for classifying participants as having Type I (late onset at age 25 or older) or Type II (early onset prior to age 25) alcoholism. There were 81 Type I (75.7%) and 26 Type II (24.3%) individuals with 4 patients unassigned due to missing data on age of onset. The previous models of drinking outcomes were repeated examining the main and interactive effects of medication group and typology. All main effects and interactions were non-significant.

4. Discussion

This placebo-controlled study did not support the hypothesis that sertraline would augment the efficacy of naltrexone in combination with group relapse prevention therapy. Although the combination group had a somewhat higher rate of abstinence compared to the naltrexone only group, this difference was not statistically significant. Moreover, there was no added benefit




Fig. 1. Time to first drink for naltrexone with sertraline ($N=57$) and naltrexone with placebo ($N=54$) groups. With missing data as censored, the analysis showed a time to first drinking day for the naltrexone plus sertraline group as 29 days (50.88% censored) vs. 18 (33.33% censored) for the naltrexone alone group, $p=0.10$.

of the combined treatment in terms of prevention of relapse to heavy drinking or on any other secondary outcomes. The negative results are in contrast to our preliminary study which compared two groups of matched patients treated open label with either the combination or naltrexone monotherapy (Farren et al., 2000), but are consistent with a recent placebo-controlled study conducted in Alaska (O'Malley et al., 2008).

The decision to recruit non-depressed individuals with alcohol dependence was made on the basis of the preclinical and clinical evidence for the general involvement of the serotonin system in alcoholism (LeMarquand et al., 1994a). In retrospect, the choice of a non-depressed group may have made a positive outcome less likely, as one prior study noted a benefit of serotonin medications in depressed alcohol dependent patients (Cornelius et al., 1997), although other studies have not (Moak et al., 2003; Kranzler et al., 2006). Type A alcohol dependent patients have been shown to benefit from SSRI's in prior research (Pettinati et al., 2000), and we conducted exploratory analyses examining alcoholism typology (early versus late onset) as a predictor of response, but did not find an advantage for the combination of sertraline and naltrexone in Type 1 or early onset patients. Possible explanations include the small sample size and the fact that all patients received active naltrexone, an effective treatment that may have obscured any potential benefit of sertraline for this subgroup. Perhaps analyses using a typology based on severity rather than age of onset might have had different results; unfortunately, we did not have the data needed to classify participants according the Babor typology (Pettinati et al., 2001; Kranzler et al., 1996).

A different dose of sertraline may have been more effective. For example, Pettinati et al. (2000) reported positive results using 200 mg daily of sertraline. Our study was initiated prior to that report, and the 100 mg dose was selected based on the results of a pilot study (Farren et al., 2000), preclinical studies (Gill et al., 1988; Higgins et al., 1992; Rezvani et al., 2000), and the possible escalation of side effects with higher doses of sertraline, particularly in combination with naltrexone. In the current study, although only sexual side effects were higher in the combination group, 40.3% (23/57) of participants in the combination group failed to complete treatment compared to 25.9% (14/54) of participants in the naltrexone only group. In addition, discontinuation due to adverse events was more common in the combination group (6 versus 2), suggesting that the potential for increased efficacy with a higher sertraline dose might be compromised by poorer tolerability, at least in combination with naltrexone. There is no evidence in the extant literature for a pharmacokinetic interaction between the two compounds that might alter either's blood levels or side effect profiles.

In conclusion, the study's findings do not support the use of 100 mg of sertraline to augment the efficacy of naltrexone for the treatment of non-depressed alcohol dependent patients. Other doses, other induction schedules or durations of treatment may have been more effective. Future trials of combination drug therapies should consider incorporating a less intensive behavioral platform, as there may be a ceiling effect when pharmacotherapies are tested with intensive psychotherapy. In the present study, all participants received naltrexone and CBT therapy, both effective

tive treatments (Anton et al., 2006), and both groups showed substantial improvements.

Conflict of interest

C. Farren has been on the speaker's panel for Pfizer Inc. and Dupont Pharma, and has been the recipient of a small unrelated research grant from Dupont Pharma.

S. O'Malley has been on the speaker's panel for Pfizer Inc. and Dupont Pharma, and has been the recipient of an unrelated research grant from Pfizer Inc. All other authors declare they have no conflict of interest.

Disclosure statement

This study was supported by RO1AA11122, K05AA014715, by the Mount Sinai GCRC, and by a small grant from Pfizer Inc. Medication was supplied by Dupont Pharma, and by Pfizer Inc. The NIAAA, nor Pfizer Inc., nor Dupont Pharma, had any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Acknowledgements

This study was supported by National Institutes of Health grants RO1AA11122, K05AA014715, by the Mount Sinai GCRC, and by the State of Connecticut, Department of Mental Health and Addiction Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institute of Health.

The authors would like to thank Dr. A. Kampov Polevoi and S. Hussein for statistical help with the protocol, and also would like to thank R. Tilton, A. Banks, R. Kranzler, and A. White for their help in data gathering for the protocol.

Contributors: Author C. Farren designed the study and wrote the protocol and wrote the first draft of the manuscript. Author M. Scimeca acted as medical director for one arm of the study, and contributed to protocol development. Author R. Wu undertook the statistical analysis, and author S. O'Malley also designed the study and wrote the protocol and contributed to statistical analysis of the protocol, and co-wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

References

- Anton, R., Moak, D.H., Latham, P., 1996. The obsessive-compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. *Arch. Gen. Psychiatry* 53, 225–231.
- Anton, R., O'Malley, S., Ciraulo, D., Cisler, R., Couper, D., Donovan, D., Hosking, J., Johnson, B., LoCastro, J., Longabaugh, R., Mason, B., Mattson, M., Miller, W., Pettinati, H., Randall, C., Swift, R., Weiss, R., Williams, L., Zweben, A., 2006. Combination pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized clinical trial. *JAMA* 295, 2003–2017.

- Beck, A., Ward, C., Mendelson, M., 1961. An inventory for measuring depression. *Arch. Gen. Psychiatry* 3, 461–471.
- Cornelius, J., Salloum, I., Ehler, J., 1997. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. *Arch. Gen. Psychiatry* 54, 700–770.
- Del Boca, F., Kranzler, H., Brown, J., Korner, P., 1996. Assessment of medication compliance through UV light detection of a riboflavin tracer. *Alcohol Clin. Exp. Res.* 20, 1412–1417.
- Farren, C.K., Rezvani, A.H., Overstreet, D., O'Malley, S., 2000. Combination pharmacotherapy in alcoholism: a novel treatment approach. *CNS Spectrums* 5, 70–76.
- Garbutt, J.C., et al., 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA* 293 (13), 1617–1625.
- Gill, K., Amit, Z., Koe, B.K., 1988. Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. *Alcohol* 5, 349–354.
- Higgins, G.A., Tomkins, D.M., Fletcher, P.J., Sellers, E.M., 1992. Effect of drugs influencing 5-HT function on ethanol drinking and feeding behavior in rats: studies using a drinkometer system. *Neurosci. Biobehav. Rev.* 16, 535–552.
- Johnson, B., Ait-Daoud, N., Prihoda, T., 2000. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypothesis to preliminary clinical evidence. *Alcohol Clin. Exp. Res.* 24, 737–742.
- Keifer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kahn, P., Stracke, R., Baehr, M., Naber, D., Wiedermann, K., 2003. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. *Arch. Gen. Psychiatry* 60, 92–99.
- Kranzler, H., Burleson, J., Brown, J., Babor, T., 1996. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. *Alcohol Clin. Exp. Res.* 20, 1534–1541.
- Kranzler, H., Van Kirk, J., 2001. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. *Alcohol Clin. Exp. Res.* 25, 1334–1341.
- Kranzler, H.R., et al., 2004. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. *Alcohol Clin. Exp. Res.* 28, 1051–1059.
- Kranzler, H., Mueller, T., Cornelius, J., Pettinati, H.M., Moak, D., Martin, P.R., Anthenelli, R., Brower, K., O'Malley, S., Mason, B.J., Hasin, D., Keller, M., 2006. Sertraline treatment of co-occurring alcohol dependence and major depression. *J. Clin. Psychopharmacol.* 26, 13–20.
- Le, A., Poulos, C., Harding, S., Watchus, J., Juzysch, W., Shaham, Y., 1999. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. *Neuropsychopharmacology* 21, 435–444.
- LeMarquand, D., Pihl, R., Benkelfat, C., 1994a. Serotonin and alcohol intake, abuse and dependence: clinical evidence. *Biol. Psychiatry* 36, 326–337.
- LeMarquand, D., Pihl, R., Benkelfat, C., 1994b. Serotonin and alcohol intake, abuse and dependence: findings of animal studies. *Biol. Psychiatry* 36, 395–421.
- Mann, K., 2004. Pharmacotherapy of alcohol dependence: a review of the clinical data. *CNS Drugs* 18, 485–504.
- McLellan, A., Luborsky, L., Woody, G., O'Brien, C., 1980. An improved diagnostic instrument for substance abuse subjects: the addiction severity index. *J. Nerv. Ment. Disorders* 168, 26–33.
- Moak, D.H., Anton, R.F., Latham, P.K., Voronin, K.E., Waid, R.L., Durazo-Arvizu, R., 2003. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. *J. Clin. Psychopharmacol.* 23, 553–562.
- O'Malley, S., Jaffe, A., Chang, G., Schottenfeld, R., Meyer, R., Rounsaville, B., 1992. Naltrexone and coping skills therapy for alcohol dependence. *Arch. Gen. Psychiatry* 49, 881–887.
- O'Malley, S.S., Garbutt, J.C., Gastfriend, D.R., Dong, Q., Kranzler, H.R., 2007. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. *J. Clin. Psychopharmacol.* 27, 507–512.
- O'Malley, S.S., Robin, R.W., Levenson, A.L., GreyWolf, I., Chance, L.E., Hodgkinson, C.A., Romano, D., Robinson, J., Meandzija, B., Stillner, V., Wu, R., Goldman, D., 2008. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska Natives and non-Natives residing in rural settings: a randomized controlled trial. *Alcohol Clin. Exp. Res.* (published article online: 14-May-2008).
- Pettinati, H.M., O'Brien, C.P., Rabinowitz, A.R., Wortman, S.P., Oslin, D.W., Kampman, K.M., Dackis, C.A., 2006. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. *J. Clin. Psychiatry* 26, 610–625.
- Pettinati, H., Volpicelli, J., Kranzler, H., Luck, G., Rukstalis, M., Cnaan, A., 2000. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. *Alcohol Clin. Exp. Res.* 24, 1041–1049.
- Pettinati, H., Volpicelli, J., Luck, G., Kranzler, H., Rukstalis, M., Cnaan, A., 2001. Double-blind clinical trial of sertraline treatment for alcohol dependence. *J. Clin. Psychopharmacol.* 21, 143–153.
- Project-Match R.G., 1997. Matching alcoholism treatment to client heterogeneity: project MATCH posttreatment drinking outcomes. *J. Stud. Alcohol* 58, 7–29.
- Rezvani, A., Overstreet, D., Mason, G., Janowsky, D., Hamedi, M., Clarke, E.J., Yang, Y., 2000. Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. *Alcohol* 35, 76–83.
- Sobell, L., Sobell, M., Leo, G., Cancell, A., 1988. Reliability of a timeline method: assessing normal drinker reports of recent drinking and a comparative evaluation across several populations. *Brit. J. Addict.* 83, 393–402.
- Spitzer, R., Williams, J., 1992. Structured Clinical Interview for DSM IV. Biometric Research Department, New York State Psychiatric Institute, New York.
- Tiihonen, J., Ryyanen, O., Kauhanen, J., Hakola, H., Salaspuro, M., 1996. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. *Pharmacopsychiatry* 29, 27–29.
- Volpicelli, J., Alterman, A., Hayashida, M., O'Brien, C., 1992. Naltrexone in the treatment of alcohol dependence. *Arch. Gen. Psychiatry* 49, 876–880.
- Zink, R.W., Rohrbach, K., Froehlich, J.C., 1997. Naltrexone and fluoxetine act synergistically to decrease alcohol intake. *Alcohol Clin. Exp. Res.* 21 (Suppl.), 104A.